Tag - AGRX

Markets

Maxim upgrades Agile on financing and contraceptive tailwind

Maxim Group upgraded Agile Therapeutics (NASDAQ:AGRX) to “buy” from “hold” and set a $1 price target, after the company closed a recent equity offering, enacted austerity measures and refined its commercial efforts. The...

July 26, 2022

Markets

Maxim cuts Agile Therapeutics to hold; removes PT

Maxim Group downgraded Agile Therapeutics (NASDAQ:AGRX) to “hold” from “buy” and removed its price target, citing a financing overhang. The stock closed at 16 cents on April 7. Analyst Naz Rahman writes that Agile ended...

April 8, 2022

Markets

Maxim ups Agile Therapeutics PT to $8 from $3

Maxim Group raised its price target for Agile Therapeutics (NASDAQ:AGRX) to $8 from $3 after the FDA approved the company’s weekly contraceptive patch, Twirla. The stock closed at $4.07 on Feb. 14. Agile shares...

February 18, 2020

Markets

WB ups Agile Therapeutics to OP

William Blair upgraded Agile Therapeutics (NASDAQ:AGRX) to “outperform” after an FDA advisory committee voted overwhelmingly to approve its resubmitted NDA for the Twirla transdermal combined hormonal contraceptive...

October 31, 2019

Feature

Agile readies new confirmatory pivotal trial of contraceptive patch

By Len Zehr Agile Therapeutics (NASDAQ:AGRX) believes it has addressed the issues raised by the FDA last year about an initial pivotal trial of its Twirla contraceptive patch and is on track to treat the first patient...

July 29, 2014

Tag - AGRX

Maxim upgrades Agile on financing and contraceptive tailwind

Maxim cuts Agile Therapeutics to hold; removes PT

Maxim ups Agile Therapeutics PT to $8 from $3

WB ups Agile Therapeutics to OP

Agile readies new confirmatory pivotal trial of contraceptive patch

General

More